By Notice dated may 2, 2003, and published in the Federal Register on May 29, 2003, (68 FR 32089), Roche Diagnostics corporation, Attn: Regulatory Compliance, 9115 Hague Road, Indianapolis, Indiana 46250, made application by renewal to the Drug Enforcement Administration to be registered as a bulk manufacturer of the basic classes of controlled substances listed below:
|Lysergic Acid Diethylamide (7515)||I|
The firm plans to manufacture small quantities of controlled substances for use in diagnostic products.
No comments or objections have been received. DEA has considered the factors in Title 21, United States Code, Section 823(a) and determined that the registration of Rocke Diagnostics Start Printed Page 52227Corporation to manufacture the listed controlled substances is consistent with the public interested at this time. DEA has investigated Roche Diagnostics Corporation to insure that the company's registration is consistent with the public interest. This investigation has included inspection and testing of the company's physical security systems, verification of the company's compliance with state and local laws, and a review of the company's background and history. Therefore, pursuant to 21 U.S.C. 823 and 28 CFR 0.100 and 0.104, the Deputy Assistant Administrator, Office of Diversion Control, hereby orders that the application submitted by the above firm for registration as a bulk manufacturer of the basic classes of controlled substances listed in granted.Start Signature
Dated: August 19, 2003.
Laura M. Nagel,
Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration
[FR Doc. 03-22323 Filed 8-29-03; 8:45 am]
BILLING CODE 4410-09-M